The timing of docetaxel initiation in metastatic castrate-sensitive prostate cancer and the rate of chemotherapy-induced toxicity

Igal Kushnir(Tel Aviv University), M. Neil Reaume(The University of Melbourne), Dominick Bossé(Dana-Farber Cancer Institute), Kim Koczka(University of Ottawa), Christina Canil(Ottawa Hospital), Elham Sabri(Ottawa Hospital), Michael Ong(Ottawa Hospital)
Medical Oncology
January 21, 2019
10.1007/s12032-018-1238-9
Cited by 7

Related Papers

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|3.7k
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
|JAMA Oncology|2017|846
Age of Transfused Blood in Critically Ill Adults
|New England Journal of Medicine|2015|559
Long term risk of symptomatic recurrent venous thromboembolism after discontinuation of anticoagulant treatment for first unprovoked venous thromboembolism event: systematic review and meta-analysis
|BMJ|2019|316
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
|Journal for ImmunoTherapy of Cancer|2018|267